Celea Biotech Secures $180 Million in Funding
Celea, a biotech company focused on idiopathic pulmonary fibrosis, has successfully raised $180 million in a funding round. This significant investment reflects growing interest in innovative therapies and could enhance the company's research and development capabilities.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.